Wellhope(SH:603609)2017-10-27 16:00Financial Performance - Operating revenue for the first nine months reached CNY 9,994,575,058.15, a 17.86% increase year-on-year[5] - Net profit attributable to shareholders decreased by 10.80% to CNY 264,150,712.94 compared to the same period last year[5] - Total operating revenue for the third quarter reached ¥3,994,092,469.45, a 16.5% increase from ¥3,427,911,749.15 in the same period last year[20] - Net profit for the third quarter was ¥175,975,415.99, representing a 38.5% increase compared to ¥127,000,637.74 in the previous year[21] - The company achieved a total profit of ¥201,087,291.98, up from ¥144,490,443.67 in the same quarter last year[21] Cash Flow - Cash flow from operating activities turned positive with a net amount of CNY 202,559,318.66, compared to a negative cash flow of CNY -4,448,301.61 in the previous year[5] - The net cash flow from operating activities for the first nine months of 2017 was ¥202,559,318.66, a significant improvement compared to a net outflow of ¥4,448,301.61 in the same period last year[25] - Total cash inflow from operating activities increased to ¥10,059,430,686.05, up from ¥8,373,960,370.45, representing a growth of approximately 20.1% year-over-year[25] - Cash outflow for purchasing goods and services rose to ¥8,879,412,282.98, compared to ¥7,606,321,205.88 in the previous year, indicating an increase of about 16.7%[25] - The ending balance of cash and cash equivalents was ¥656,718,580.99, compared to ¥595,202,530.49 at the end of the same period last year, reflecting an increase of about 10.3%[26] Assets and Liabilities - Total assets increased by 16.34% to CNY 6,014,414,757.56 compared to the end of the previous year[5] - The company's total liabilities increased to ¥2,478,872,554.68 from ¥1,848,313,530.57, reflecting a significant rise in short-term borrowings[15] - Current assets totaled ¥2,994,796,190.82, an increase from ¥2,627,013,804.37 at the beginning of the year[14] - The total equity attributable to shareholders reached ¥3,183,746,981.93, compared to ¥3,006,170,941.93 at the beginning of the year[15] Shareholder Information - The number of shareholders reached 33,219, with the top ten shareholders holding significant stakes[6] Financial Assets and Investments - The company reported a 648.33% increase in financial assets measured at fair value, amounting to CNY 1,075,713.05[8] - The company reported an investment income of ¥48,420,286.06, significantly higher than ¥21,195,243.30 in the previous year[21] Expenses - Financial expenses rose by 46.19% to ¥45,940,514.39 due to an increase in short-term loans and interest expenses[12] - Sales expenses increased to ¥113,608,981.96, compared to ¥100,399,981.04 in the same period last year[20] - Management expenses rose to ¥68,095,190.64, up from ¥62,178,416.69 year-over-year[20] - Financial expenses increased to ¥15,176,642.88, compared to ¥11,314,416.19 in the previous year[20] Accounts Receivable and Inventory - Accounts receivable increased by 119.04% to CNY 665,006,188.64 due to new settlement periods[8] - The inventory balance as of September 30, 2017, was ¥1,190,246,182.81, slightly down from ¥1,195,567,396.95 at the beginning of the year[14] Other Income - The company received other income of ¥5,967,000.00 from government subsidies during the reporting period[12] - The company’s deferred income increased by 71.00% to CNY 8,550,000.00, reflecting an increase in government subsidies related to assets[8] Asset Impairment - Asset impairment losses increased by 35.75% to ¥42,920,142.78, attributed to higher provisions for bad debts[12] Production Assets - The company has seen a significant increase in production biological assets, which rose by 31.65% to CNY 13,569,361.11[8]